These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21182475)

  • 1. Emerging targets for the treatment of dyslipidemia.
    Tavridou A; Ragia G; Manolopoulos VG
    Curr Med Chem; 2011; 18(6):909-22. PubMed ID: 21182475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery Approaches for Novel Dyslipidemia Drugs.
    Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
    Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel molecules targeting dyslipidemia and atherosclerosis.
    Tavridou A; Manolopoulos VG
    Curr Med Chem; 2008; 15(8):792-802. PubMed ID: 18393849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging options in the treatment of dyslipidemias: a bright future?
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):247-70. PubMed ID: 21323473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of dyslipidemia.
    Kampangkaew J; Pickett S; Nambi V
    Curr Opin Cardiol; 2017 Jul; 32(4):348-355. PubMed ID: 28505047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents to manage dyslipidemias and impact atherosclerosis.
    Nachimuthu S; Raggi P
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):209-17. PubMed ID: 17017903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of diabetic dyslipidemia.
    Filippatos TD; Florentin M; Georgoula M; Elisaf MS
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):187-200. PubMed ID: 27868450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.